Abstract
The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell diseases characterized by cytopenia(s) due to ineffective hematopoiesis accompanied by dysplasia in one or more myeloid cell lines and an increased risk of development of acute leukemia. A correct diagnosis and classification of MDS requires integration of morphology with clinical data and ancillary studies including cytogenetics and next-generation sequencing to detect submicroscopic pathogenic variants. Assessment of morphologic dysplasia relies on review of adequately stained peripheral blood smear, bone core biopsy, and bone marrow aspirate smears. In addition, the blast count is predictive of progression to acute leukemia and should be obtained from a careful assessment of 200 cells in the peripheral blood and 500 cells on the bone marrow aspirate. The chapter summarizes morphologic dysplasia for each of the lineages in the context of the diagnostic criteria for the WHO-defined MDS categories (see Table 10.1 and reference [1]). It is now recognized that cytopenia is invariably implicit in the diagnosis of MDS and the clinical behavior is influenced by the number of dysplastic lineages and the blast count [2]. The WHO revision therefore proposes to change the nomenclature to eliminate the use of refractory anemia and refractory cytopenia and replace it with “myelodysplastic syndrome” with further subclassification relying on the dysplastic lineages and the blast count (Tables 10.1 and 10.2) (Figs. 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 10.10, 10.11, 10.12, 10.13, 10.14, 10.15, 10.16, 10.17, 10.18, 10.19, 10.20, 10.21, 10.22, 10.23, 10.24, 10.25, 10.26, 10.27, 10.28, 10.29, 10.30, 10.31, 10.32, 10.33, 10.34, 10.35, 10.36, 10.37, 10.38, 10.39, and 10.40).
Access provided by CONRICYT-eBooks. Download chapter PDF
Similar content being viewed by others
Keywords
The myelodysplastic syndromes (MDS) are clonal hematopoietic stem cell diseases characterized by cytopenia(s) due to ineffective hematopoiesis accompanied by dysplasia in one or more myeloid cell lines and an increased risk of development of acute leukemia. A correct diagnosis and classification of MDS requires integration of morphology with clinical data and ancillary studies including cytogenetics and next-generation sequencing to detect submicroscopic pathogenic variants. Assessment of morphologic dysplasia relies on review of adequately stained peripheral blood smear, bone core biopsy, and bone marrow aspirate smears. In addition, the blast count is predictive of progression to acute leukemia and should be obtained from a careful assessment of 200 cells in the peripheral blood and 500 cells on the bone marrow aspirate. The chapter summarizes morphologic dysplasia for each of the lineages in the context of the diagnostic criteria for the WHO-defined MDS categories (see Table 10.1 and reference [1]). It is now recognized that cytopenia is invariably implicit in the diagnosis of MDS and the clinical behavior is influenced by the number of dysplastic lineages and the blast count [2]. The WHO revision therefore proposes to change the nomenclature to eliminate the use of refractory anemia and refractory cytopenia and replace it with “myelodysplastic syndrome” with further subclassification relying on the dysplastic lineages and the blast count (Table 10.1 (Figs. 10.1, 10.2, 10.3, 10.4, 10.5, 10.6, 10.7, 10.8, 10.9, 10.10, 10.11, 10.12, 10.13, 10.14, 10.15, 10.16, 10.17, 10.18, 10.19, 10.20, 10.21, 10.22, 10.23, 10.24, 10.25, 10.26, 10.27, 10.28, 10.29, 10.30, 10.31, 10.32, 10.33, 10.34, 10.35, 10.36, 10.37, 10.38, 10.39, and 10.40).
References
Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127:2391–405.
Arber DA, Hasserjian RP. Reclassifying myelodysplastic syndromes: what’s where in the new WHO and why. Hematology Am Soc Hematol Educ Program. 2015;2015:294–8.
Germing U, Strupp C, Giagounidis A, Haas R, Gattermann N, Starke C, et al. Evaluation of dysplasia through detailed cytomorphology in 3156 patients from the Dusseldorf registry on myelodysplastic syndromes. Leuk Res. 2012;36:727–34.
Willis MS, Monaghan SA, Miller ML, McKenna RW, Perkins WD, Levinson BS, et al. Zinc-induced copper deficiency: a report of three cases initially recognized on bone marrow examination. Am J Clin Pathol. 2005;123:125–31.
Papaemmanuil E, Cazzola M, Boultwood J, Malcovati L, Vyas P, Bowen D, et al. Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med. 2011;365:1384–95.
Malcovati L, Karimi M, Papaemmanuil E, Ambaglio I, Jädersten M, Jansson M, et al. SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts. Blood. 2015;126:233–41.
Vardiman JW. Hematopathological concepts and controversies in the diagnosis and classification of myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2006:199–204.
Grossmann V, Bacher U, Haferlach C, Schnittger S, Pötzinger F, Weissmann S, et al. Acute erythroid leukemia (AEL) can be separated into distinct prognostic subsets based on cytogenetic and molecular genetic characteristics. Leukemia. 2013;27:1940–3.
Willis MS, McKenna RW, Peterson LC, Coad JE, Kroft SH. Low blast count myeloid disorders with Auer rods: a clinicopathologic analysis of 9 cases. Am J Clin Pathol. 2005;124:191–8.
Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, et al. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia. 2012;26:1286–92.
Baumann I, Führer M, Behrendt S, Campr V, Csomor J, Furlan I, et al. Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria. Histopathology. 2012;61:10–7.
Niemeyer CM, Baumann I. Classification of childhood aplastic anemia and myelodysplastic syndrome. Hematology Am Soc Hematol Educ Program. 2011;2011:84–9.
Hasle H. Myelodysplastic and myeloproliferative disorders of childhood. Hematology Am Soc Hematol Educ Program. 2016;2016:598–604.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2018 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Gurbuxani, S. (2018). Myelodysplastic Syndrome. In: George, T., Arber, D. (eds) Atlas of Bone Marrow Pathology. Atlas of Anatomic Pathology. Springer, New York, NY. https://doi.org/10.1007/978-1-4939-7469-6_10
Download citation
DOI: https://doi.org/10.1007/978-1-4939-7469-6_10
Published:
Publisher Name: Springer, New York, NY
Print ISBN: 978-1-4939-7467-2
Online ISBN: 978-1-4939-7469-6
eBook Packages: MedicineMedicine (R0)